recent
newer
synthet
dna
vaccin
rapidli
advanc
clinic
studi
demonstr
impress
degre
immun
potenc
toler
improv
dna
deliveri
prior
needl
syring
approach
includ
jet
deliveri
gene
gun
deliveri
among
other
among
effect
new
deliveri
method
advanc
electropor
ep
combin
advanc
induc
robust
humor
cellular
immun
prevent
well
therapeut
studi
advanc
design
dna
insert
includ
leader
sequenc
chang
rna
codon
optim
improv
insert
design
increas
concentr
dna
skin
deliveri
appear
complement
newer
deliveri
strategi
advanc
also
provid
framework
vivo
product
synthet
dna
biolog
review
focu
recent
studi
synthet
dna
vaccin
clinic
prevent
treatment
infecti
diseas
focu
adapt
electropor
deliveri
briefli
summar
novel
preclin
data
advanc
vivo
deliveri
dnaencod
antibodylik
biolog
vaccin
among
import
medic
intervent
human
histori
era
unpreced
scientif
advanc
vaccin
technolog
howev
develop
new
vaccin
face
challeng
due
multipl
factor
includ
high
cost
develop
drive
focu
larger
market
slower
optim
time
line
vaccin
advanc
clinic
test
among
complex
one
exampl
increas
occurr
emerg
reemerg
infect
appear
sporad
could
benefit
greatli
rapid
vaccin
intervent
exampl
includ
lassa
powasan
viru
zika
viru
zikv
ebola
viru
ebov
coronavirusesmiddl
east
respiratori
syndrom
coronaviru
merscov
sever
acut
respiratori
syndrom
coronaviru
among
mani
other
ideal
vaccin
platform
simpl
deploy
rapid
develop
reproduc
temperatur
stabl
consist
manufacturablethu
lower
cost
develop
risk
provid
import
new
tool
synthet
dna
syndna
platform
address
mani
import
goal
dna
immunogen
directli
design
optim
pathogen
sequenc
synthes
allow
flexibl
speed
preclin
test
rapid
transit
clinic
scale
vivo
express
construct
sequenc
facilit
rapid
screen
select
potenti
vaccin
candid
multipl
studi
report
syndna
allow
gener
cellular
humor
respons
pathogen
impact
challeng
model
system
origin
intramuscular
im
inocul
recent
intraderm
id
deliveri
use
highli
concentr
formul
induc
consist
immun
clinic
deliveri
method
jet
deliveri
gene
gun
deliveri
nanoparticl
deliveri
other
demonstr
increas
dna
uptak
vivo
adapt
electropor
ep
control
energi
deliv
vivo
ep
improv
increas
transform
effici
needl
syring
deliveri
follow
local
inject
needl
syring
plasmid
dna
taken
limit
number
cell
site
inject
dna
transcrib
mrna
translat
antigen
intracellularli
adapt
ep
increas
initi
uptak
plasmid
local
cell
approxim
creat
larg
antigen
bolu
drive
potent
immun
respons
adapt
ep
cell
local
field
transfect
local
transfect
antigenpres
cell
apc
directli
traffic
region
lymph
node
ln
critic
initi
immun
respons
translat
antigen
shed
exogen
pick
apc
cross
present
shed
exogen
solubl
antigen
drain
local
region
ln
extracellular
space
local
environ
allow
engag
b
cell
immun
local
tissu
becom
protein
factori
present
antigen
major
histocompat
mhc
mhc
ii
molecul
reexpans
ln
prime
cell
cytotox
lymphocyt
ctl
cell
respect
figur
comprehens
review
see
ref
sinc
dna
plasmid
deliv
ten
thousand
patient
multipl
rout
trial
studi
numer
vaccin
antigen
target
highli
consist
safeti
record
support
clinic
develop
discuss
recent
clinic
studi
use
syndna
platform
figur
specif
focu
dna
vaccin
target
emerg
reemerg
infecti
diseas
cancer
infecti
etiolog
million
new
human
immunodefici
infect
occur
annual
highlight
need
effect
prophylact
vaccin
two
multicent
random
clinic
trial
immunogen
syndna
construct
encod
clade
b
gag
pol
env
protein
pennvaxb
dna
vaccin
pv
alon
combin
plasmidencod
evalu
hvtn
without
hvtn
intramuscular
ep
vaccin
safe
welltoler
addit
molecular
plasmid
encod
ep
deliveri
result
dose
spare
effect
immunogen
superior
vaccin
electropor
fewer
dose
demonstr
dosespar
effect
combin
platform
vaccin
group
ep
deliveri
vaccine
detect
hivspecif
cell
respons
three
immun
venezuelan
equin
enceph
viru
veev
mosquitoborn
alphaviru
recogn
biosafeti
threat
human
approv
vaccin
therapeut
hannaman
et
al
studi
dna
vaccin
target
gene
veev
subtyp
iab
envelop
compar
intraderm
versu
intramuscular
electropor
ep
variou
dose
small
number
human
subject
studi
high
dose
intramuscular
ep
result
develop
veev
neutral
antibodi
subject
intradermalep
promot
neutral
antibodi
lower
level
fewer
subject
cell
respons
report
studi
increas
dna
deliveri
coupl
highli
effici
encod
antigen
product
allow
local
deliveri
becom
sourc
product
biolog
insert
highli
design
allow
local
express
multipl
public
describ
dnaencod
monoclon
antibodi
dmab
bispecif
antibodi
immunogen
use
target
cancer
infecti
diseas
zika
viru
zikv
mosquitoborn
infecti
diseas
character
fever
rash
conjunct
malais
despit
rel
mild
clinic
ill
zikv
infect
pregnanc
associ
sever
congenit
birth
defect
microcephali
first
zika
vaccin
advanc
clinic
syndna
vaccin
deliv
adapt
ep
teba
et
al
evalu
safeti
immunogen
synthet
dna
vaccin
target
zika
prme
phase
doserang
studi
particip
receiv
either
mg
zikv
dna
immunogen
deliv
id
rout
cellectraep
week
third
immun
zikaspecif
bind
antibodi
detect
particip
averag
titer
mg
dose
group
higher
dose
group
particip
develop
zikaneutr
antibodi
detect
via
neuron
cell
assay
importantli
passiv
transfer
studi
patient
serum
given
interferon
knockout
mice
suscept
zikv
infect
show
sera
vaccin
subject
protect
mice
lethal
pathogen
zikv
challeng
zikvspecif
cell
induc
subject
zikv
dna
vaccin
move
research
program
initi
clinic
month
highlight
effici
speed
synthet
dna
platform
brought
bear
emerg
reemerg
pathogen
vaccin
research
center
vrc
nation
institut
health
report
result
two
zikv
dna
vaccin
trial
vrc
evalu
safeti
immunogen
dna
plasmid
encod
prm
e
protein
zikvjapanes
enceph
viru
jev
chimera
deliv
mg
dose
either
vrc
nativ
leader
like
zikv
vaccin
vaccin
mg
dose
immun
three
time
differ
interv
vrc
gmt
averag
per
group
vrc
gmt
rang
vaccin
induc
neutral
titer
use
report
assay
show
cell
mediat
cytokin
releas
author
suggest
vaccin
group
develop
consist
seroconvers
neutral
cell
immun
jev
chimer
zika
vaccin
ebola
viru
ebov
caus
agent
sever
viral
hemorrhag
diseas
human
nonhuman
primat
synthet
dna
vaccin
prime
time
approach
gari
weiner
select
recent
dna
vaccin
clinic
report
construct
found
safe
immunogen
clinic
sever
report
clinic
impact
outcom
repres
import
immun
readout
date
twentynin
ebov
outbreak
mortal
rate
reach
patel
et
al
report
rapid
vivo
protect
mice
follow
singl
immun
synthet
dna
vaccin
encod
consensu
ebov
glycoprotein
gp
repres
ebov
outbreak
strain
span
year
heterolog
mouseadapt
ebov
strain
synebovgp
dna
immun
also
result
protect
macaqu
lethal
ebov
challeng
importantli
studi
determin
dosespar
regimen
deliv
via
recent
character
intradermalep
cellectraep
rout
protect
lethal
challeng
respons
persist
one
year
immun
robust
recal
respons
observ
time
point
promis
result
support
first
inhuman
fih
clinic
trial
two
ebovgp
candid
encod
synconebovgp
antigen
repres
outbreak
strain
ino
encod
zair
makona
ebovgp
outbreak
evalu
alon
togeth
combin
dnaencod
human
deliv
either
im
id
rout
use
cellectra
ep
deliveri
rout
induc
potent
antiebola
cellular
humor
immun
howev
id
deliveri
rout
dose
spare
promot
rapid
seroconvers
seroreact
immun
simplic
consist
toler
id
format
appear
exhibit
import
advantag
vaccin
develop
emerg
reemerg
pathogen
could
support
role
current
vsvzebov
vaccin
middl
east
respiratori
syndrom
coronaviru
merscov
first
identifi
respons
outbreak
case
cluster
arabian
peninsula
first
spread
mer
nonarabian
peninsula
countri
seoul
korea
gener
major
outbreak
muthumani
et
al
report
develop
synthet
dna
vaccin
encod
mer
spike
protein
induc
potent
humor
cellmedi
immun
mice
nonhuman
primat
camel
protect
vaccin
macaqu
mer
associ
pneumonia
follow
viru
challeng
phasei
openlabel
singlearm
doseescal
clinic
trial
open
walterre
armi
institut
research
clinic
trial
vaccin
deliv
intramuscular
inject
cellectraep
seroconvers
detect
patient
merscovspecif
cell
respons
detect
patient
persist
day
postfin
immun
influenza
virus
undergo
antigen
drift
shift
requir
new
vaccin
design
annual
curb
diseas
spread
recent
vrc
nih
publish
two
clinic
studi
jet
deliv
dna
prime
match
trival
inactiv
viru
boost
influenza
vaccin
regimen
healthi
adult
volunt
children
compar
inactiv
viru
prime
boost
dna
prime
viru
boost
induc
trend
toward
greater
humor
respons
includ
hemagglutinin
inhibit
hai
neutral
find
collect
demonstr
abil
rapidli
appli
synthet
dna
platform
context
infecti
diseas
eid
potent
immun
perform
well
excel
toler
profil
platform
human
papilloma
virus
hpv
oncogen
virus
infect
mucos
surfac
hpv
respons
almost
cancer
worldwid
recombin
hpv
particlebas
vaccin
specif
oncogen
hpv
two
strain
hpv
gener
genit
wart
impact
incid
hpv
infect
howev
person
alreadi
infect
remain
high
risk
collect
hpv
diseas
includ
cervic
cancer
head
neck
cancer
anal
cancer
vagin
cancer
other
hpvassoci
cancer
firstinhuman
fih
clinic
trial
advanc
test
hypothesi
synthet
dna
vaccin
encod
hpv
immunogen
modifi
nuclear
oncogen
hpv
type
two
high
risk
genotyp
would
induc
ctl
might
impact
hpvinduc
cervic
intraepitheli
neoplasia
cin
initi
immunogen
studi
report
vaccin
highli
immunogen
drive
antibodi
ctl
almost
vaccin
subject
followup
phase
iib
efficaci
trail
subsequ
report
studi
show
potent
induct
immun
includ
cell
migrat
diseas
cervic
tissu
overal
women
studi
regress
diseas
regress
clear
cervic
infect
first
therapeut
vaccin
show
clinic
efficaci
grade
cin
addit
studi
approach
cin
progress
report
also
first
treatment
efficaci
data
gener
dna
approach
human
diseas
syndna
platform
potenti
synerg
extant
cancer
therapi
clinic
mcneel
et
al
report
combin
immunotherapi
tcell
stimul
dna
vaccin
welltoler
promot
antitumor
respons
recent
studi
agarwal
et
al
test
adapt
ep
deliveri
synhpv
vaccin
treatment
hpv
posit
head
neck
cancer
phase
ibii
safeti
toler
immunogen
studi
report
result
immunotherapi
dna
immunotherapi
target
codeliv
plasmid
deliv
adapt
cellectraep
twentytwo
patient
local
advanc
head
neck
squamou
cell
carcinoma
hnscc
receiv
overal
treatment
well
toler
evalu
patient
show
elev
antigenspecif
tcell
activ
ifng
elispot
persist
cellular
respons
surpass
spotform
unit
sfu
peripher
blood
mononuclear
cell
pbmc
note
year
induct
hpvspecif
cell
observ
tumor
post
biopsi
one
patient
develop
metastat
diseas
flowcytometr
analys
reveal
induct
cell
found
treatment
patient
therapi
result
rapid
durabl
complet
respons
data
demonstr
induc
clear
durabl
antigenspecif
peripher
tumorinfiltr
immun
respons
may
benefit
patient
context
check
point
inhibitor
cpi
therapi
improv
therapeut
outcom
interestingli
group
report
second
complet
respond
context
cpi
combin
therapi
addit
studi
approach
ongo
clinicaltrialsgov
identifi
combin
cpi
potent
cell
gener
syndna
vaccin
repres
import
tool
addit
studi
broader
context
cancer
immunotherapi
use
biolog
modifi
biolog
treat
variou
diseas
rapidli
expand
similarli
immun
disord
cancer
may
treat
monoclon
antibodi
target
cancerspecif
antigen
immunosuppress
molecul
present
immun
cell
cytotox
tlymphocyteassoci
protein
program
cell
inde
immunotherapi
success
clinic
becom
standard
care
cancer
treatment
approach
recent
report
describ
use
syndnaencod
monoclon
antibodi
dmab
therapi
deliv
immunotherapi
vivo
bispecif
antibodi
engag
cancer
target
cytotox
lymphocyt
lead
cellmedi
kill
cancer
cell
grow
clinic
import
first
fda
approv
bispecif
blincyto
blinatumomab
target
b
cell
treatment
acut
lymphoblast
leukemia
bispecf
drug
complex
produc
short
halfliv
associ
high
cost
per
treatment
limit
develop
patient
access
take
account
high
local
product
tissu
new
syndna
ig
product
approach
offer
altern
product
pipelin
biolog
extens
approach
peralespuchalt
report
vivo
deliveri
sever
month
express
dna
encod
bispecif
antibodi
deliv
directli
vivo
demonstr
potent
tumor
control
mous
model
support
deliveri
nonn
ig
form
earli
report
describ
use
plasmid
vector
system
gener
antibodi
like
molecul
well
envelop
neutral
f
ab
xu
malign
dmab
dmab
produc
rapidli
persist
mous
sera
extend
therapeut
window
immun
checkpoint
blockad
therapi
malign
dmab
dmab
rapidli
produc
vivo
shrink
tumor
mous
cancer
model
malign
dmabdbit
dmab
bispecif
target
induc
control
ovarian
tumor
mice
prolong
surviv
use
syndna
platform
express
sulfat
antibodylik
entri
inhibitor
illustr
potenti
complex
vivo
biolog
assembl
recent
wise
et
al
report
dmab
encod
hivspecif
broadli
neutral
antibodi
could
produc
function
broadli
neutral
antibodi
mice
nonhuman
primat
platform
continu
advanc
dmab
target
influenza
b
dengu
chikungunya
zika
ebola
protect
anim
model
dmab
may
also
provid
advantag
antibacteri
therapeut
complement
antibiot
patel
et
al
report
optim
dmab
target
bacterium
pseudomona
aeruginosa
protect
lethal
pneumonia
mous
model
antibioticresist
p
aeruginosa
similarli
wang
et
al
report
design
dmab
target
borrelia
protein
ospa
could
protect
challeng
borreliainfect
tick
block
lyme
diseas
transmiss
gut
feed
tick
mous
challeng
model
recent
studi
illustr
grow
interest
dmab
approach
addit
studi
area
like
high
import
flexibl
approach
prevent
treatment
infecti
diseas
well
cancer
therapi
tabl
bring
mani
advantag
simpl
dna
deliveri
platform
synthet
dna
platform
dramat
chang
perform
last
year
combin
advanc
improv
deliveri
dna
cell
increas
toler
combin
multipl
chang
genet
design
formul
result
potent
vaccin
platform
mani
featur
import
rapid
vaccin
develop
deploy
emerg
infecti
diseas
later
stage
trial
vaccin
worthi
signific
attent
extens
studi
conserv
nonvir
cancer
target
similarli
uniqu
import
recent
anim
research
studi
show
diseas
impact
biolog
deliveri
monoclon
bispecif
antibodi
dmab
prime
expans
dnaencod
biolog
investig
infecti
diseas
cancer
therapi
preclin
set
result
first
advanc
dmab
clinic
clinicaltri
gov
identifi
origin
pioneer
dna
vaccin
paper
suggest
conceptu
develop
deploy
advantag
simpl
nucleic
acidbas
vaccin
platform
impact
host
global
diseas
recent
advanc
synthet
dna
technolog
brought
us
step
closer
import
outcom
may
import
implic
develop
vaccin
newli
emerg
dbw
grant
fund
particip
industri
collabor
receiv
speak
honoraria
fee
consult
servic
includ
serv
scientif
review
committe
advisori
board
remuner
includ
direct
payment
stocksstock
option
interest
disclosur
therefor
note
potenti
conflict
associ
work
particular
inovio
serv
bodsab
well
pfizer
bristolmy
squibb
merck
aldevron
roch
fer
pharmaceut
possibl
other
